Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Down 1.4%

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) dropped 1.4% during mid-day trading on Monday . The company traded as low as $2.79 and last traded at $2.89. Approximately 207,775 shares changed hands during trading, a decline of 77% from the average daily volume of 901,097 shares. The stock had previously closed at $2.93.

UNCY has been the subject of several recent research reports. Roth Capital initiated coverage on shares of Unicycive Therapeutics in a research report on Monday, August 9th. They issued a “buy” rating and a $13.50 price target for the company. Benchmark initiated coverage on shares of Unicycive Therapeutics in a research report on Tuesday, August 17th. They issued a “buy” rating for the company.

The business’s 50-day moving average is $2.89.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Monday, August 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). Equities analysts predict that Unicycive Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

About Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics Inc is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company’s lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc is based in LOS ALTOS, Calif.

Featured Article: Call Option

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.